Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Shares Outstanding (Weighted Average) (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Shares Outstanding (Weighted Average) for 10 consecutive years, with $73.8 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Shares Outstanding (Weighted Average) rose 12.27% year-over-year to $73.8 million, compared with a TTM value of $73.8 million through Dec 2023, up 12.27%, and an annual FY2023 reading of $73.8 million, up 12.27% over the prior year.
  • Shares Outstanding (Weighted Average) was $73.8 million for Q4 2023 at CytomX Therapeutics, down from $80.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $80.7 million in Q3 2023 and bottomed at $45.1 million in Q1 2019.
  • Average Shares Outstanding (Weighted Average) over 5 years is $58.5 million, with a median of $64.6 million recorded in 2021.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 41.78% in 2021, then grew 0.63% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $45.3 million in 2019, then increased by 1.79% to $46.1 million in 2020, then soared by 39.01% to $64.1 million in 2021, then grew by 2.48% to $65.7 million in 2022, then increased by 12.27% to $73.8 million in 2023.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CTMX at $73.8 million in Q4 2023, $80.7 million in Q3 2023, and $66.5 million in Q2 2023.